- FDA Expands Indications for Regorafenib
- EMA Recommends Approval of Two Biosimilar Medicines – Biosimilar Rituximab
- EMA Recommends Granting a Marketing Authorisation for Inotuzumab Ozogamicin
- EMA Recommends Extension of Indications for Bevacizumab
- NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC
- FDA Grants Regular Approval to Palbociclib as Initial Endocrine Based Therapy
- FDA Grants Regular Approval to Osimertinib
- EMA Recommends Granting a Marketing Authorisation Under Exceptional Circumstances for Dinutuximab beta Apeiron
- FDA Approves PARP Inhibitor Niraparib
- Giovanni Codacci-Pisanelli
- FDA Approves Ribociclib as Initial Treatment for Postmenopausal Women with HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
- EMA Reviewing Cancer Medicine Docetaxel
- Use of imatinib in CML has pointed oncology in a new direction
- Clarification of Hepatitis B Virus Status Needed Before Starting Treatment with Pomalidomide
- EMA Recommends Granting a Marketing Authorisation for Pemetrexed Hospira UK Limited
- EMA Recommends Extensions of Indication for Daratumumab
- EMA Recommends Extensions of Indications for Dabrafenib and Trametinib
- FDA Approves Lenalidomide as Maintenance Therapy for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant
- Phase II Study Supports Potential for Atezolizumab plus Bevacizumab for Locally Advanced or Metastatic Renal Cell Carcinoma
- FDA Accepts Two sBLAs for Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings
- European Patent Office Decision on Dasatinib
- Bevacizumab Ruled Out As Adjuvant Therapy for Resectable Gastro-oesophageal Cancer
- EMA Recommends Granting a Marketing Authorisation for Hybrid Methotrexate
- EMA Recommends Extension of Indications for Lenalidomide in Multiple Myeloma
- NICE Issues Technology Appraisal Guidance for Ibrutinib for Previously Treated CLL and Untreated CLL with 17p Deletion or TP53 Mutation